Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance

References

• American Society for Reproductive Medicine. Use of insulin sensitizing agents in the treatment of polycystic ovary syndrome. A practice committee report. American Society for Reproductive Medicine, Washington, DC 2000
   Google Scholar
• Kolodziejczyk B, Duleba A J, Spaczynski R Z, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149–1154
   PubMed Web of Science ®Google Scholar
• Nestler J E, Stovall D, Akhter N, Iuorno M J, Jakubowicz D J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril 2002; 77: 209–215
   PubMed Web of Science ®Google Scholar
• Velazquez E M, Mendoza S, Hamer T, Sosa F, Glueck C J. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism 1994; 43: 647–654
   PubMed Web of Science ®Google Scholar
• Huber-Buchholz M M, Carey D GP, Norman R J. Restoration of reproductive potential by lifestyle modification in obese polycystic ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab 1999; 84: 1470–1474
   PubMed Web of Science ®Google Scholar
• Hoeger K M, Kochman L, Wixom N, Craig K, Miller R K, Guzick D S. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Fertil Steril 2004; 82: 421–429
   PubMed Web of Science ®Google Scholar
• Pawelczyk L, Spaczynski R Z, Banaszewska B, Duleba A J. Metformin therapy increases insulin-like growth factor binding protein-1 in hyperinsulinemc women with polycystic ovaries syndrome. Eur J Obstet Gynecol Reprod Biol 2004; 113: 209–213
   PubMed Web of Science ®Google Scholar
• Balen A H, Laven J S, Tan S L, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update 2003; 9: 505–514
   PubMed Web of Science ®Google Scholar
• The Rotterdam ESHRE/ASRAM-sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41–47
   Google Scholar
• Ferriman D, Gallwey J D. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 1961; 21: 1440–1447
   PubMed Web of Science ®Google Scholar
• Kelly C, Vankrieken L. Sex hormone binding globulin and the assessment of androgen status. DPC technical report. Diagnostic Products Corporation, Los Angeles, CA 1997
   Google Scholar
• Vermeulen A, Verdonck L, Kaufman J M. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666–3672
   PubMed Web of Science ®Google Scholar
• Crave J C, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 1995; 80: 2057–2062
   PubMed Web of Science ®Google Scholar
• Duleba A, Pawelczyk L A, Yuen B H, Moon Y S. Insulin actions on ovarian steroidogenesis are not modulated by metformin. Hum Reprod 1993; 8: 1194–1198
   Google Scholar
• Maciel G A, Soares Junior J M, Alves da Motta E L, Abi Haidar M, de Lima G R, Baracat E C. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Fertil Steril 2004; 81: 355–360
   PubMed Web of Science ®Google Scholar
• Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 1997; 18: 774–800
   PubMed Web of Science ®Google Scholar
• Azziz R, Woods K S, Reyna R, Key T J, Knochenhauer E S, Yildiz B O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745–2749
   PubMed Web of Science ®Google Scholar
• Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol–cyprotrone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study. Hum Reprod 2002; 17: 1729–1737
   PubMed Web of Science ®Google Scholar
• Santana L F, de Sa M F, Ferriani R A, de Moura M D, Foss M C, dos Reis R M. Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome. Gynecol Endocrinol 2004; 19: 88–96
   PubMed Web of Science ®Google Scholar
• Clark A M, Ledger W, Galletly C, Tomlinson L, Blaney F, Wang X, Norman R J. Weight loss results in significant improvement in pregnancy and ovulation rates in anovulatory obese women. Hum Reprod 1995; 10: 2705–2712
   PubMed Web of Science ®Google Scholar
• Norman R J. Polycystic ovary syndrome. Med J Aust 2004; 180: 132–137
   PubMed Web of Science ®Google Scholar
• Goldenberg N, Glueck C J, Loftspring M, Sherman A, Wang P. Metformin–diet benefits in women with polycystic ovary syndrome in the bottom and top quintiles for insulin resistance. Metabolism 2005; 54: 113–121
   PubMed Web of Science ®Google Scholar
• Cibula D. Is insulin resistance an essential component of PCOS? The influence of confounding factors. Hum Reprod 2004; 19: 757–759
   PubMedGoogle Scholar
• Diamanti-Kandarakis E. Therapeutic effects of metformin on insulin resistance and hyperandrogenism in polycystic ovary syndrome. Eur J Endocrinol 1998; 138: 269–274
   PubMed Web of Science ®Google Scholar
• Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L. Metformin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrheic women with the polycystic ovary syndrome. Metabolism 1999; 48: 511–519
   PubMed Web of Science ®Google Scholar
• Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 2000; 85: 139–146
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J, Evans W S, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998; 338: 1876–1880
   PubMed Web of Science ®Google Scholar
• Legro R S, Finegood D, Dunaif A. A fasting glucose to insulin ratio is useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998; 83: 2694–2698
   PubMed Web of Science ®Google Scholar
• Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450c17α activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996; 335: 617–623
   PubMed Web of Science ®Google Scholar
• Aruna J, Mittal S, Kumar S, Misra R, Dadhwal V, Vimala N. Metformin therapy in women with polycystic ovary syndrome. Int J Gynaecol Obstet 2004; 87: 237–241
   PubMed Web of Science ®Google Scholar
• Kriplani A, Agarwal N. Effects of metformin on clinical and biochemical parameters in polycystic ovary syndrome. J Reprod Med 2004; 49: 361–367
   PubMed Web of Science ®Google Scholar
• Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S. Endocrine and metabolic effects of metformin versus ethinyl estradiol–cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study. J Clin Endocrinol Metab 2000; 85: 3161–3168
   PubMed Web of Science ®Google Scholar
• Pugeat M, Cousin P, Baret C, Lejeune H, Forest M G. Sex-hormone binding globulin during puberty in normal and hyperandrogenic girls. J Pediatr Endocrinol Metab 2000; 13(Suppl 5)1277–1279
   Google Scholar
• La Marca A, Egbe T O, Morgante G, Paglia T, Cianci A, De Leo V. Metformin treatment reduces ovarian cytochrome P-450c17α response to human chorionic gonadotrophin in women with insulin resistance-related polycystic ovary syndrome. Hum Reprod 2000; 15: 21–23
   PubMed Web of Science ®Google Scholar
• Kelly C, Gordon D. The effect of metformin on hirsutism in polycystic ovary syndrome. Eur J Endocrinol 2002; 147: 217–221
   PubMed Web of Science ®Google Scholar
• Vandermolen D T, Ratts V S, Evans W S, Stovall D W, Kauma S W, Nestler J E. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil Steril 2001; 75: 310–315
   PubMed Web of Science ®Google Scholar
• Guzick D S, Wing R, Smith D, Berga S L, Winters S J. Endocrine consequences of weight loss in obese, hyperandrogenic, anovulatory women. Fertil Steril 1994; 61: 598–604
   PubMed Web of Science ®Google Scholar
• Jakubowicz D J, Nestler J E. 17α-Hydroxyprogesterone responses to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome offer dietary weight loss. J Clin Endocrinol Metab 1997; 82: 556–560
   PubMed Web of Science ®Google Scholar
• Ciotta L, De Leo V, Farina M, Pafumi C, La Marca A, Cianci A. Endocrine and metabolic effects of insulin sensitizers in treatment of patients with polycystic ovary syndrome and hyperinsulinaemia. Gynecol Obstet Invest 2001; 51: 44–50
   PubMedGoogle Scholar